ID: ALA205659

Max Phase: Preclinical

Molecular Formula: C25H29F3N6O6

Molecular Weight: 566.54

Molecule Type: Small molecule

Representations

Canonical SMILES:  CCCC[C@H](NC(=O)O[C@@H]1C(=O)N(C(=O)Nc2ccc(C(F)(F)F)cc2)CC1(C)C)C(=O)C(=O)Nc1cc[nH]n1

Standard InChI:  InChI=1S/C25H29F3N6O6/c1-4-5-6-16(18(35)20(36)32-17-11-12-29-33-17)31-23(39)40-19-21(37)34(13-24(19,2)3)22(38)30-15-9-7-14(8-10-15)25(26,27)28/h7-12,16,19H,4-6,13H2,1-3H3,(H,30,38)(H,31,39)(H2,29,32,33,36)/t16-,19+/m0/s1

Standard InChI Key:  PTNBWGAJLBFPEI-QFBILLFUSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 566.54

Molecular Weight (Monoisotopic): 566.2101

AlogP: 3.69

#Rotatable Bonds: 9

Polar Surface Area: 162.59

Molecular Species: NEUTRAL

HBA: 7

HBD: 4

#RO5 Violations: 1

HBA (Lipinski): 12

HBD (Lipinski): 4

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 10.42

CX Basic pKa: 1.59

CX LogP: 4.63

CX LogD: 4.63

Aromatic Rings: 2

Heavy Atoms: 40

QED Weighted: 0.34

Np Likeness Score: -0.79

References

1. Barrett DG, Catalano JG, Deaton DN, Hassell AM, Long ST, Miller AB, Miller LR, Ray JA, Samano V, Shewchuk LM, Wells-Knecht KJ, Willard DH, Wright LL..  (2006)  Novel, potent P2-P3 pyrrolidine derivatives of ketoamide-based cathepsin K inhibitors.,  16  (6): [PMID:16376075] [10.1016/j.bmcl.2005.11.101]

Source

Source(1):

• Scientific Literature